Skip to content
Search

Latest Stories

E-pharmacies in India and Kenya ‘not fully’ compliant with regulatory requirements

Only 16% of Indian e-pharmacies provide complete drug information
In India, e-pharmacies currently account for 2–3% of total medicine sales, a figure anticipated to increase to 15% over the next ten years. (gettyimages)

Only 16% of Indian e-pharmacies and 42% of those in Kenya provide complete drug information

E-pharmacies in India and Kenya demonstrate low compliance with global best practices and existing or proposed national regulations, a new study has revealed.

Published in PLOS Global Public Health, the study found that none of the assessed e-pharmacies in either country was fully compliant with regulatory requirements.


On average, e-pharmacies serving Kenya met 8.9 out of 12 (74 per cent) of the country’s regulatory requirements, while those serving India complied with 7.5 out of 14 (54 per cent) ‘proposed requirements.’

The research was conducted by the George Institute for Global Health in India, in collaboration with Strathmore Business School in Kenya and the London School of Hygiene & Tropical Medicine.

E-pharmacies were defined as businesses selling prescription-only medicines (POMs) directly to consumers through websites or apps.

The study identified 61 websites and 37 apps catering to Indian consumers, alongside 26 websites and three apps serving Kenyan users.

Researchers assessed these platforms against global ‘best practice’ standards, as well as existing national regulations in Kenya and ‘proposed requirements’ from local guidelines and draft bills in India, where there are no e-pharmacy-specific regulations.

Key findings include:

  • A facility to upload prescriptions was provided by 90% of websites serving India and 58% serving Kenya.
  • Only 16% of Indian e-pharmacies and 42% of Kenyan e-pharmacies provided complete drug information, including indications, side effects, drug interactions, and contraindications.
  • Only 31% websites serving Kenya and none serving India displayed required registration numbers.
  • Despite regulations and guidelines, 62% of e-pharmacies in Kenya and 34% in India listed narcotic or controlled drugs for sale.
  • All websites serving India, and all but one serving Kenya, complied with the practice of prohibiting advertisements of POMs.

The study also found that high-traffic websites and e-pharmacies located within the study country had higher mean compliance to regulation and best practices compared to the others.

The researchers highlighted the need for a robust regulatory framework to ensure consumer safety and and maintain the quality of pharmaceutical care in the rapidly growing e-pharmacy sector in both countries.

“The study findings can be leveraged to strengthen regulatory enforcement in Kenya and inform the development of legislation and accompanying regulations for e-pharmacies in India,” they noted.

They recommend a risk-based approach to regulation, where regulators work with the largely compliant (“good”) e-pharmacies, improve enforcement among the partially compliant (“bad”), and eliminate the largely non-compliant (“ugly”).

The study cautioned that poorly regulated e-pharmacy could expose consumers to health and e-commerce-related risks.

Over the past decade, the global e-pharmacy market has witnessed significant expansion. Valued at USD 92 billion (£74.25 billion) in 2023, it is projected to surpass USD 350 billion (£282.48 billion) by 2033, with emerging markets driving the majority of this growth.

In India, e-pharmacies currently account for 2–3% of total medicine sales, a figure anticipated to increase to 15% over the next ten years.

Meanwhile, Africa’s e-pharmacy sector has seen remarkable growth, tripling from USD 190 million in 2019 (pre-COVID-19) to USD 560 million in 2022.

The African e-pharmacy market tripled from a pre-COVID-19 value of USD 190 million (£153.34 million) in 2019 to USD 560 million (451.96 million) in 2022.

More For You

NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Pharmacy First: Government confirms £215 million boost to realise its full potential

From April 2025, the consultation fee for Pharmacy First Minor Illness and Clinical Pathways will rise from £15 to £17.

‘Pharmacy First hasn't realised its full potential,’ says Stephen Kinnock

Health Minister Stephen Kinnock has acknowledged that Pharmacy First has huge potential, noting that the service “hasn't realised its full potential.”

As part of efforts to enhance the service, Kinnock yesterday (30) announced £215 million in additional funding for Pharmacy First and other Primary Care Access Recovery Plan services.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less